Abselion Secures Funding to Revolutionize Protein Analysis
Ruizhi Wang, the CEO of Abselion, is at the forefront of a significant evolution in biopharmaceutical research and development. His company, based in Cambridge, UK, specializes in the creation of automated analytical instrumentation that simplifies at-line protein quantification. Recently, Abselion secured an impressive £6.6 million in Series A funding, a monetary boost that highlights the growing interest and investment in life sciences technology. The funding round was led by M Ventures, with notable contributions from new investors including BioProcess 360 Partners and Untitled Ventures, alongside existing investors such as BGF and R42. As part of this significant investment initiative, Oliver Hardick from M Ventures and Chris Major from BioProcess 360 Partners have been appointed to the company’s Board of Directors.
The freshly acquired funds will be pivotal in driving the commercialization of Abselion’s innovative technologies and expanding the capabilities of its flagship product, the Amperia at-line protein analyser.
This benchtop instrument is engineered to enhance the process of quantifying proteins in a rapid and efficient manner, targeting the development and production of biologics like antibodies and viral vectors. Utilizing a sensitive and specific redox-electrochemical-detection (RED) technology, the Amperia system empowers scientists to derive process insights that are critical for biopharmaceutical applications. This cutting-edge technology enables researchers to quantify antibodies, adeno-associated viruses (AAVs), and other proteins directly from crude samples in just one minute, significantly improving the efficiency of life science research and bioprocessing.
Abselion's innovative approach is set to transform the landscape of protein analysis, providing researchers with essential data quickly and accurately right at the point of need. This capability not only enhances research efficiency but also plays a crucial role in the development of vital therapeutics. As the demand for rapid and reliable data continues to grow in the biopharmaceutical industry, Abselion’s advancements under Ruizhi Wang’s leadership position the company as a key player in meeting these demands. With its focus on streamlining workflows and accelerating access to critical insights, Abselion is poised to make a significant impact on both research and production within the life sciences domain.
They've invested in Abselion
Get to know these Biotech investors
Click here for a full list of 6,481+ startup investors in the UK